TelyRx Holdings Inc.
TELY.TO
Toronto Stock Exchange2.45
CAD
-0.05
- -
CIK
0002113853
ISIN
CA87974Y1043
CUSIP
87974Y104
Return %
Stock
S&P500
1Y
-30.00
18.65
3Y
-30.00
71.44
5Y
-30.00
70.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Vanessa Slowey
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 24761 US Hwy 19N Clearwater FL United States of America 33763
- IPO Date
- Apr 7, 2026
- CIK
- 0002113853
- Website
- telyrx.com
- Similar Companies
- Business
- TelyRx Holdings Inc. operates as a vertically integrated, technology-enabled healthcare and digital pharmacy services company. Through its TelyRx platform, the Company connects patients in 48 U.S. states and U.S. territories with independent, state-licensed healthcare providers for assessment and, where clinically appropriate, prescription issuance; fills prescriptions through its licensed retail pharmacies in Florida and Texas; and delivers medications directly to patients’ homes, including next-day delivery where available. Its cash-pay, direct-to-consumer platform is designed to provide access to routine prescription medications without traditional appointments, memberships or insurance requirements, subject to a provider review fee. The Company offers more than 500 common FDA-approved prescription medications addressing more than 60 health conditions, including treatments for chronic conditions; flu, infections and respiratory conditions; digestive and travel health; skin and hair care; women’s health; men’s health; lifestyle and sexual health; weight management; and pet health, as well as supplements and physician-note services. TelyRx also serves physicians, veterinarians, practice groups and other licensed prescribers through pharmacy and prescription-fulfillment services. Founded in 2019 and headquartered in Clearwater, Florida, TelyRx Holdings Inc. became the public parent of TelyRx, Inc. following the completion of a qualifying reverse-takeover transaction with Apolo V Acquisition Corp. in March 2026; Apolo V subsequently changed its name to TelyRx Holdings Inc., and its subordinate voting shares began trading on the Toronto Stock Exchange under the symbol TELY in April 2026. In connection with the transaction, TelyRx Finco Inc. completed a brokered private placement generating gross proceeds of approximately US$35.9 million. Recent strategic developments include the June 2026 commencement of OTCQX trading in the United States under the symbol TELYF, the expansion of its Clearwater operations to approximately triple its footprint to support digital-healthcare demand, the surpassing of one million prescriptions filled nationwide, and the August 2026 launch of a new consumer brand platform and redesigned digital experience featuring enhanced medication discovery, transparent pricing and delivery tracking, alongside an expansion of the formulary from approximately 400 medications at the beginning of 2026 to more than 500 medications.